MedTrace Logo

Pregnancy and Postpartum CGM in GDM

NCT07174245 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2025-09-15

No results posted yet for this study

Summary

Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Conditions

  • Gestational Diabetes

Interventions

DEVICE

continuous glucose monitor

All participants who wear CGM

Sponsors & Collaborators

Principal Investigators

  • Grenye O'Malley, MD · Icahn School of Medicine at Mount Sinai

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-05
Primary Completion
2026-08-05
Completion
2026-08-15
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07174245 on ClinicalTrials.gov